Search

Genmab A-S

Uždarymo kaina

3,902 3.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3763

Max

3944

Pagrindiniai rodikliai

By Trading Economics

Pajamos

243M

295M

Pardavimai

259M

1.2B

P/E

Sektoriaus vid.

36.557

50.373

Pelnas, tenkantis vienai akcijai

34.85

Pelno marža

25.541

Darbuotojai

3,119

EBITDA

216M

431M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-1.49% downside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

69B

182B

Ankstesnė atidarymo kaina

3898.96

Ankstesnė uždarymo kaina

3902

Genmab A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-30 23:56; UTC

Scholar Rock Holding Corporation's shares are trading modestly lower in after-market hours, retracing from an early peak following a brief uptick after Friday's close.

2026-10-30 23:56; UTC

Surgery Partners, Inc. is trading modestly lower in after-market hours, settling at its lowest point despite a brief recovery earlier in the session.

2026-10-30 23:56; UTC

Aquestive Therapeutics, Inc. is trading modestly higher in after-market hours following a notable increase after an initial dip earlier in the session.

2026-10-30 23:56; UTC

Patterson-UTI Energy Inc shares traded modestly lower in after-market hours, retracing some gains after a brief improvement following Friday's close.

2026-10-30 23:56; UTC

Avantor, Inc. shares are declining in after-market trading, continuing a downward trend since Friday's close and reaching their lowest point late in the session.

2026-10-30 23:56; UTC

Xometry, Inc. is trading modestly higher in after-market hours, reaching a peak since Friday's close despite an initial dip.

2026-10-30 23:56; UTC

Social Media

Take-Two Interactive Software, Inc. shares are trading modestly higher in after-market hours.

2026-10-30 23:56; UTC

Krispy Kreme, Inc. shares are trading modestly lower in after-market hours, following a recent decline.

2026-10-30 23:56; UTC

LyondellBasell Industries N.V. is trading lower in after-market hours, with a cumulative return decrease from a low of -1.30% to -0.58% since Friday's close.

2026-10-30 23:56; UTC

Canadian Solar Inc. is trading modestly lower in after-market hours, following a slight recovery from an earlier decline at the market close.

2026-10-30 23:56; UTC

The Nikkei 225 Index declined during after-market hours, continuing a downward trend amid broader market weakness and slowing business activity indicated by Chicago PMI data.

2026-10-30 23:56; UTC

ConocoPhillips shares are trading lower in after-market hours, having retraced from an earlier peak and remaining down since Friday's close.

2026-10-30 23:56; UTC

Pool Corporation shares traded modestly lower in after-market hours, continuing a decline that began after Friday's close.

2026-10-30 23:56; UTC

Wingstop Inc. is trading lower in after-market hours, having earlier dipped as much as 1.51% from Friday's close.

2026-10-30 23:56; UTC

Fastenal Company shares are trading modestly higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

2026-10-30 23:56; UTC

AAON, Inc. shares are modestly higher in after-market trading, recovering from recent weakness.

2026-10-30 23:52; UTC

Australia's Balance of Trade report on November 5 expected to show AUD 1 billion surplus, reflecting strong resource exports and positive market sentiment.

2026-10-30 23:52; UTC

Brazil's Industrial Production MoM data release on November 5, 2026, raises cautious market expectations amid ongoing declines and economic challenges.

2026-10-30 23:51; UTC

Champion Homes Inc. is trading modestly lower in after-market hours, having retraced from a brief peak earlier in the session.

2026-10-30 23:51; UTC

Sarepta Therapeutics, Inc. is trading modestly higher in after-market hours after a strong upward movement from a low point shortly after the market closed.

2026-10-30 23:51; UTC

Social Media

In after-market hours, Lowe's shares traded lower, retracing from earlier gains to below Friday's close, despite discussions on its dividend performance.

2026-10-30 23:51; UTC

Herc Holdings Inc. is trading lower in after-market hours, reversing an earlier uptick and declining since Friday's close.

2026-10-30 23:51; UTC

Cabaletta Bio, Inc. shares declined in after-market trading after a volatile session, currently positioned below its 20-day moving average and near the month's lower range.

2026-10-30 23:51; UTC

The New York Times Company is trading higher in after-market hours, reaching a high above its 20-day moving average and near the upper end of its one-month range.

2026-10-30 23:51; UTC

W. P. Carey Inc. has advanced modestly in after-market trading, reaching a high point near the upper end of its one-month trading range.

2026-10-30 23:51; UTC

Axsome Therapeutics, Inc. is advancing in after-market trading.

2026-10-30 23:51; UTC

News

FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.

2026-10-30 23:51; UTC

News

BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.

2026-10-30 23:51; UTC

Goodyear Tire & Rubber Co is trading modestly higher in after-market hours, recovering from earlier fluctuations during the session.

2026-10-30 23:51; UTC

News

Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.

Akcijų palyginimas

Kainos pokytis

Genmab A-S Prognozė

Kainos tikslas

By TipRanks

-1.49% į apačią

12 mėnesių prognozė

Vidutinis 2,493.35 DKK  -1.49%

Aukščiausias 3,320 DKK

Žemiausias 308.417 DKK

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Genmab A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

3

Pirkti

2

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat